S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
A 'soft landing' or a recession? How each one might affect America's households and businesses
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Friday, 12/8/2023
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
MarketBeat Week in Review – 12/4 - 12/8
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
A 'soft landing' or a recession? How each one might affect America's households and businesses
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Friday, 12/8/2023
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
MarketBeat Week in Review – 12/4 - 12/8
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
A 'soft landing' or a recession? How each one might affect America's households and businesses
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Friday, 12/8/2023
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
MarketBeat Week in Review – 12/4 - 12/8
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
A 'soft landing' or a recession? How each one might affect America's households and businesses
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Friday, 12/8/2023
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
MarketBeat Week in Review – 12/4 - 12/8
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod

Diaceutics Share Price, News & Analysis (LON:DXRX)

GBX 92
0.00 (0.00%)
(As of 12/8/2023 ET)
Compare
Today's Range
90
92.50
50-Day Range
83.15
105
52-Week Range
74
118
Volume
6,167 shs
Average Volume
54,748 shs
Market Capitalization
£77.73 million
P/E Ratio
10,500.00
Dividend Yield
N/A
Price Target
GBX 150

DXRX stock logo

About Diaceutics Stock (LON:DXRX)

Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics. The company also provides DXRX lab education, a suite of tailored and targeted training sessions designed to provide essential education for labs to enable and drive quality testing and biomarker knowledge; DXRX advisory boards that create and enable a valuable interface for pharmaceutical companies with a view to exploring and revealing new insights pertinent to the commercialisation and development of a therapy or companion diagnostic; and DXRX Lab Alerts, an advanced laboratory targeting service delivering tailored, short-form, quick read, educational messages with call-to-action to labs in the DXRX network. In addition, it offers implementation and consulting services for precision medicine diagnostics. Diaceutics PLC was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.

DXRX Stock Price History

DXRX Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Diaceutics PLC (DXRX.L)
Is this FTSE AIM stock primed for growth in 2022?
See More Headlines
Receive DXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Diaceutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Diagnostics & Research
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Phone
N/A
Fax
N/A
Employees
151
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 150
High Stock Price Target
GBX 150
Low Stock Price Target
GBX 150
Potential Upside/Downside
+63.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£21.90 million
Cash Flow
GBX 29.49 per share
Book Value
GBX 49 per share

Miscellaneous

Free Float
N/A
Market Cap
£77.73 million
Optionable
Not Optionable
Beta
0.45
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Peter Keeling (Age 62)
    Founder, CEO & Executive Director
    Comp: $363.24k
  • Mr. Nicholas Stewart Roberts (Age 40)
    CFO & Director
    Comp: $180.37k
  • Mr. Ryan Keeling (Age 40)
    Executive Director
    Comp: $334.27k
  • Ms. Julie Browne
    Chief Operating Officer
  • Ms. Gillian Shaw
    General Counsel
  • Ms. Norma Thompson
    Global Head of Human Resources
  • Mr. Jordan Clark
    Chief Commercial Officer
  • Ms. Susanne Munksted
    Chief Precision Medicine Officer
  • Ms. Jillian Beggs
    Chief Commercial Officer
  • Ms. Marieke Hoefsmit
    Senior Director & Head of Data Delivery Netherlands














DXRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Diaceutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Diaceutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DXRX shares.
View DXRX analyst ratings
or view top-rated stocks.

What is Diaceutics' stock price target for 2024?

2 Wall Street research analysts have issued 1 year price targets for Diaceutics' stock. Their DXRX share price targets range from GBX 150 to GBX 150. On average, they predict the company's share price to reach GBX 150 in the next year. This suggests a possible upside of 63.0% from the stock's current price.
View analysts price targets for DXRX
or view top-rated stocks among Wall Street analysts.

How have DXRX shares performed in 2023?

Diaceutics' stock was trading at GBX 75.50 at the start of the year. Since then, DXRX stock has increased by 21.9% and is now trading at GBX 92.
View the best growth stocks for 2023 here
.

How do I buy shares of Diaceutics?

Shares of DXRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:DXRX) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -